 |
PDBsum entry 5imm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immune system
|
PDB id
|
|
|
|
5imm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Structural evaluation of a nanobody targeting complement receptor vsig4 and its cross reactivity.
|
|
|
Authors
|
|
Y.Wen,
Z.Ouyang,
S.Schoonooghe,
S.Luo,
P.De baetselier,
W.Lu,
S.Muyldermans,
G.Raes,
F.Zheng.
|
|
|
Ref.
|
|
Immunobiology, 2017,
222,
807-813.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
Vsig4 is a recently identified immune regulatory protein related to the B7
family with dual functionality: a negative regulator of T cell activation and a
receptor for the complement components C3b and C3c. Here we present a structural
evaluation of a nanobody, Nb119, against the extracellular IgV domain protein of
both mouse and human recombinant Vsig4, which have a high degree of sequence
identity. Although mouse and human Vsig4 bind to Nb119 with a 250 times
difference in dissociation constants, the interaction results in a highly
identical assembly with a RMSD of 0.4Å. The molecular determinants for Vsig4
recognition and cross reactivity unveiled by the atomic structure of Nb119 in
complex with mVsig4 and hVsig4 afford new insights useful for the further
optimization of the nanobody for potential use in humans. Additionally,
structural analysis of the Vsig4-Nb119 complexes indicates that Nb119 occupies
the interface on Vsig4 recognized by the macroglobulin-like domains MG4 and MG5
of C3b. Thus an affinity-improved Nb119 may have the potential to influence the
activation of both T cells and complement.
|
|
|
|
|
|
|
